Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.62 |
| ▸ | CALML3 | P27482 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328625 | 1.00 | MAOA (0.62) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL3328729 | 0.97 | MAOA (0.64) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL3326680 | 0.93 | MAOA (0.63) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL6070468 | 0.91 | MAOA (0.62) | MAOACALML3CYP3A4CYP2D6 | |
| SCHEMBL3328705 | 0.90 | MAOA (0.57) | MAOACALML3MAOB | |
| SCHEMBL3327326 | 0.90 | MAOA (0.60) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL3326672 | 0.90 | MAOA (0.61) | MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL3327186 | 0.90 | MAOA (0.72) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL3328142 | 0.89 | MAOA (0.56) | MAOACALML3MAOB | |
| SCHEMBL3328144 | 0.89 | MAOA (0.56) | MAOACALML3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | MAOA 482/4885CALML3 4624/4885MAOB 192/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | MAOA 800/4885CALML3 4637/4885MAOB 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.